Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine and carboplatin priming followed by avelumab for anti-PD1-resistant metastatic melanoma
ACTRN12618000053224Phase 2Terminated
- Sponsor
- University of Newcastle
- Start
- Mar 2018
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of azacitidine, carboplatin and avelumab in melanoma, sponsored by University of Newcastle. Primary endpoints: RECIST 1.1 response after azacitidine/carboplatin, RECIST 1.1 response after avelumab induction and 1 more. Started Mar 2018; status: terminated.
02
Drugs
azacitidinecarboplatinavelumab
03
Conditions
melanoma
Beyond the preview
Go deeper on ACTRN12618000053224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000053224.